Dr. Roth Compares Surgery With SBRT in Lung Cancer

Jack A. Roth, MD
Published: Friday, Sep 18, 2015



Jack A. Roth, MD, professor, Department of Thoracic and Cardiovascular Surgery, chief, Section of Thoracic Molecular Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, compares surgery with stereotactic body radiation therapy (SBRT) in patients with early-stage lung cancer.

Surgery, which often involves a lobectomy, has been the standard of care for patients with early-stage lung cancer for years, Roth explains. With this procedure, these patients have a greater than 70% chance of being disease-free for 5 years. This has been shown to be an effective treatment, Roth says, so long as the disease is in early stage.

In recent years, SBRT has emerged as a treatment for early-stage patients who cannot undergo surgery due to poor pulmonary function and other comorbidities that would make surgery too risky, Roth says. Local control rates for SBRT have been greater than 90%.



Jack A. Roth, MD, professor, Department of Thoracic and Cardiovascular Surgery, chief, Section of Thoracic Molecular Oncology, Division of Surgery, University of Texas MD Anderson Cancer Center, compares surgery with stereotactic body radiation therapy (SBRT) in patients with early-stage lung cancer.

Surgery, which often involves a lobectomy, has been the standard of care for patients with early-stage lung cancer for years, Roth explains. With this procedure, these patients have a greater than 70% chance of being disease-free for 5 years. This has been shown to be an effective treatment, Roth says, so long as the disease is in early stage.

In recent years, SBRT has emerged as a treatment for early-stage patients who cannot undergo surgery due to poor pulmonary function and other comorbidities that would make surgery too risky, Roth says. Local control rates for SBRT have been greater than 90%.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x